Literature DB >> 28529338

Glomerular disease: Targeted steroid therapy for IgA nephropathy.

Richard J Glassock1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28529338     DOI： 10.1038/nrneph.2017.65

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  8 in total

1.  Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

Authors:  Bengt C Fellström; Jonathan Barratt; Heather Cook; Rosanna Coppo; John Feehally; Johan W de Fijter; Jürgen Floege; Gerd Hetzel; Alan G Jardine; Francesco Locatelli; Bart D Maes; Alex Mercer; Fernanda Ortiz; Manuel Praga; Søren S Sørensen; Vladimir Tesar; Lucia Del Vecchio
Journal:  Lancet       Date:  2017-03-28       Impact factor: 79.321

2.  A cortisol suppression dose-response comparison of budesonide in controlled ileal release capsules with prednisolone.

Authors:  S Edsbäcker; M Nilsson; P Larsson
Journal:  Aliment Pharmacol Ther       Date:  1999-02       Impact factor: 8.171

3.  The gut-kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition.

Authors:  Rosanna Coppo
Journal:  Pediatr Nephrol       Date:  2017-04-07       Impact factor: 3.714

Review 4.  Low bioavailability and traditional systemic steroids in IBD: can the former take over the latter?

Authors:  Federica Fasci Spurio; Annalisa Aratari; Giovanna Margagnoni; Valeria Clemente; Alessandra Moretti; Claudio Papi
Journal:  J Gastrointestin Liver Dis       Date:  2013-03       Impact factor: 2.008

5.  Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

Authors:  Thomas Rauen; Frank Eitner; Christina Fitzner; Claudia Sommerer; Martin Zeier; Britta Otte; Ulf Panzer; Harm Peters; Urs Benck; Peter R Mertens; Uwe Kuhlmann; Oliver Witzke; Oliver Gross; Volker Vielhauer; Johannes F E Mann; Ralf-Dieter Hilgers; Jürgen Floege
Journal:  N Engl J Med       Date:  2015-12-03       Impact factor: 91.245

6.  Krüppel-Like Factor 15 Mediates Glucocorticoid-Induced Restoration of Podocyte Differentiation Markers.

Authors:  Sandeep K Mallipattu; Yiqing Guo; Monica P Revelo; Lucia Roa-Peña; Timothy Miller; Jason Ling; Stuart J Shankland; Agnieszka B Bialkowska; Victoria Ly; Chelsea Estrada; Mukesh K Jain; Yuan Lu; Avi Ma'ayan; Anita Mehrotra; Rabi Yacoub; Edward P Nord; Robert P Woroniecki; Vincent W Yang; John C He
Journal:  J Am Soc Nephrol       Date:  2016-06-10       Impact factor: 10.121

7.  Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial.

Authors:  Claudio Pozzi; Simeone Andrulli; Lucia Del Vecchio; Patrizia Melis; Giovanni B Fogazzi; Paolo Altieri; Claudio Ponticelli; Francesco Locatelli
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

8.  Moderator's view: Treatment of IgA nephropathy-getting comfortable with uncertainty.

Authors:  Richard J Glassock
Journal:  Nephrol Dial Transplant       Date:  2016-08-11       Impact factor: 5.992
  8 in total
  2 in total

1.  Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria.

Authors:  Liu Xiaowei; Wang Bo; Li Li; Zhang Peng
Journal:  Int Urol Nephrol       Date:  2019-11-25       Impact factor: 2.266

2.  Efficacy and Safety of Glycosides of Tripterygium wilfordii Combined with Renin-Angiotensin System in the Treatment of IgA Nephropathy: A Systematic Review and Meta-Analysis.

Authors:  Ming Chen; Peiqing Zhang; Lianhua Li; Zhuo Yu; Na Liu; Lifan Wang
Journal:  Emerg Med Int       Date:  2022-09-30       Impact factor: 1.621
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.